Literature DB >> 23006937

Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma.

Brian I Carr1, Vito Guerra, Petr Pancoska.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) size at diagnosis is important in management. Without screening programs, tumor size at diagnosis is heterogeneous. AIMS: To examine the clinical parameters related to tumor size.
METHODS: Using prospectively collected data from a 1,100-patient biopsy-proven HCC cohort presenting in the absence of screening, tumor sizes were ordered and trichotomized and the resulting terciles were compared for tumor and blood parameters.
RESULTS: The terciles were significantly different with respect to portal hypertension and thrombocytopenia, which were present in a higher percent of tercile I patients with smaller tumors. Tercile III patients with larger HCCs had the highest serum α-fetoprotein (AFP), γ-glutamyl transpeptidase (GGTP), and alkaline phosphatase (ALKP) levels and the most portal vein (PV) thrombosis. Subclassification of tercile I patients by AFP showed that patients with high serum AFP had increased numbers of tumor nodules, more PV thrombosis, higher bilirubin, ALKP, and GGTP levels, and shorter survival.
CONCLUSIONS: Smaller-tumor tercile I patients had more advanced portal hypertension with thrombocytopenia than did larger-tumor patients. Tercile I patients with higher AFP levels had more frequent PV thrombosis and worse survival than those with lower AFP levels. Elevated serum GGTP and ALKP levels appear to be associated with a more aggressive HCC phenotype. These differing patterns suggest more than one HCC pathway.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23006937     DOI: 10.1159/000342431

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  18 in total

1.  Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.

Authors:  Rosalba D'Alessandro; Maria Grazia Refolo; Catia Lippolis; Nicola Carella; Caterina Messa; Aldo Cavallini; Brian Irving Carr
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-24       Impact factor: 3.333

2.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

3.  Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.

Authors:  Petr Pancoska; Brian I Carr; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Semin Oncol       Date:  2014-04-24       Impact factor: 4.929

4.  Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis.

Authors:  Petr Pančoška; Lubomír Skála; Jaroslav Nešetřil; Brian I Carr
Journal:  Semin Oncol       Date:  2015-01-05       Impact factor: 4.929

5.  Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma.

Authors:  Zhixiong Long; Bin Wang; Dan Tao; Yanping Liu; Jiangzhou Zhang; Jiaan Tan; Jing Luo; Feifei Shi; Zezhang Tao
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

6.  Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.

Authors:  Hikmet Akkiz; Brian I Carr; Kendal Yalçın K; Vito Guerra; Sedef Kuran; Engin Altıntaş; Oğuz Üsküdar; Ümit Karaoğullarından; Ayşegül Özakyol; Salih Tokmak; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Tuğsan Ballı; Ali Demir; Burcu Arslan; Figen Doran
Journal:  Oncology       Date:  2017-12-06       Impact factor: 2.935

7.  Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.

Authors:  Petr Pancoska; Sheng-Nan Lu; Brian I Carr
Journal:  J Gastrointest Dig Syst       Date:  2013-03-02

8.  Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.

Authors:  Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Semin Oncol       Date:  2014-03-06       Impact factor: 4.929

9.  Thrombocytosis and hepatocellular carcinoma.

Authors:  Brian I Carr; Vito Guerra
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

10.  Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase.

Authors:  Brian I Carr; Vito Guerra
Journal:  Oncology       Date:  2013-08-29       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.